As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The debate over how to tackle America's obesity epidemic that affects 40% of adults and nearly 20% of children, has sparked ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Ozempic is technically a diabetes medication, but its maker Novo Nordisk markets a related product called Wegovy for weight ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...

But once the shortage is over, patent enforcements go back into full swing. Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for ...

But, with the outsized demand for Mounjaro and Zepbound and Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, it has become a ...

Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have ...